LIDDS refinanced in February this year, through a rights issue, and the company does not view further such financing as a near-term option, but it is instead fully committed to cutting costs to maximally extend the runway to reach a license agreement for Liproca® Depot and/or other assets with existing funding. This will require cost containment measures on all expenses not invested in the licensing process. A cut-back on staff will also be considered.

Given the significant decrease in company operations caused by this decision, the Board has reached an agreement with CEO, Anders Månsson, which means that he will work part-time as CEO until end August, and after that he will leave the company to pursue other opportunities. LIDDS’s management, board and Alira Health will continue to work on the licensing projects until a result is reached. There are several interested stakeholders in the process, and LIDDS must ensure that a potential negotiation is not impaired by the time constraints of diminishing cash and the need to re-finance mid-process. Halting long-term investments, such as further clinical development, until the licensing process can be concluded, aims to serve that very purpose.

“These are obviously very tough decisions” says Pontus Ottosson, newly elected Chairman of the Board at LIDDS. “However, as consistently communicated in recent months, LIDDS has several assets in the pipeline including the Phase III-ready Liproca® Depot product candidate that could move the needle significantly funding wise through a licensing agreement. Succeeding in the licensing of a product candidate or other projects is imperative both as regards to funding, and in terms of providing a proof of concept that pipeline products built on LIDDS’s technology, NanoZolid®, have a value in the market. I am convinced that economising and fully focusing on succeeding in these licensing projects, before initiating further studies, is the right decision for the company and its shareholders.”